10: Assessing DNA variants for antisense oligonucleotide therapy

Cheerie D et al., The American Journal of Human Genetics - This episode summarizes the N1C VARIANT consensus guidelines (version 1.0) that define a framework to evaluate pathogenic DNA variants for eligibility for antisense oligonucleotide (ASO) approaches, and describes the supporting tools, videos, and piloting process developed by the N¼1 Collaborative. Key terms: antisense oligonucleotides, variant eligibility, N1C VARIANT, splice correction, exon skipping.

Study Highlights:
An international working group developed the N1C VARIANT guidelines to assess variant amenability to ASO strategies including splice correction, exon skipping, transcript knockdown, and upregulation of the wild-type allele. The guidelines use a five-tier classification scheme: eligible, likely eligible, unlikely eligible, not eligible, and unable to assess. Development included iterative piloting with multidisciplinary volunteer assessors, training videos, and an interactive eligibility calculator. The guidelines and resources are intended for clinicians, laboratories, and researchers prioritizing candidates for individualized ASO development.

Conclusion:
The N1C VARIANT guidelines provide a practical, consensus-based framework, training materials, and an eligibility calculator to systematically assess pathogenic variants for ASO therapies, with planned yearly updates to reflect advances in the field.

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-04-18.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 8
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- The N1C VARIANT guidelines provide the first international consensus framework to evaluate which genetic variants are amenable to antisense oligonucleotide (ASO) therapies, using a
- The N1C variant eligibility calculator is an interactive HTML/JS tool with forced pathway logic that prevents moving forward without specific data entry.
- The five-tier definitions distinguish between variants with functional evidence (eligible), strong molecular criteria without functional data (likely eligible), and cases where the
- The guideline process is designed to be updated yearly and to include evolving ASO technologies (e.g., allele-selective gapmer approaches).
- ASOs have multiple mechanisms of action, including transcript knockdown, exon skipping, splice correction, and upregulation of the wild-type allele; eligibility depends on variant
- A variant classified as eligible does not guarantee patient eligibility; disease stage and reversibility of damage must be considered

QC result: Pass.